分子診斷儀器及試劑市場機會、成長要素、產業趨勢分析及2026-2035年預測。

2025年全球分子診斷儀器和試劑市場價值為185億美元，預計到2035年將以7.6%的複合年成長率成長至386億美元。

推動市場成長的因素包括技術的持續進步、人們對疾病早期檢測意識的提高、對即時診斷（POC）解決方案日益成長的需求以及全球老齡化人口的不斷擴大。分子診斷儀器和試劑包括診斷設備、分析儀、檢測溶液和耗材，它們透過分析DNA、RNA和其他分子標記等遺傳物質來識別和監測疾病。這些產品廣泛應用於臨床診斷、傳染病檢查、癌症篩檢、基因分析和科研領域，但不包括軟體和資訊平台。感染疾病率的上升、新病原體的出現以及感染疾病的反覆爆發，使得人們迫切需要更快、更準確的診斷技術。醫療系統越來越重視早期檢測、準確識別疾病以及有效應對感染的傳播，這推動了醫院、檢查室和研究機構對分子診斷儀器、檢測套組和試劑的採用。

預計到2025年，試劑和試劑盒細分市場將佔據71.9%的市場。試劑和試劑盒是分子診斷工作流程中不可或缺的組成部分，它們對於傳染病篩檢、腫瘤學、基因診斷和產前檢測等各環節的檢測程序都至關重要。由於檢測量不斷成長和診斷程序的擴展，對這些耗材的需求仍然強勁。此外，檢測方法的進步、多重檢測能力的提升以及針對特定疾病的專用檢測組合的出現，都提高了分子診斷的效率和準確性。實驗室和醫療專業人員對可靠、標準化且易於使用的檢測解決方案的需求日益成長，也進一步推動了該細分市場的擴張。

到2025年，醫院和診所將佔據45.9%的市場。醫療機構正日益將分子診斷技術融入日常臨床實踐，用於疾病識別、治療方案製定、患者監測和持續護理管理。隨著對精準診斷資訊的需求不斷成長，醫院和診所正受益於分子檢測在其醫療流程中的更廣泛應用。患者數量的增加、醫療投資的擴大以及對提高診斷準確性的需求，正推動醫療機構加強其分子檢測能力。

預計到2025年，北美分子診斷儀器和試劑市場將佔據42.4%的市場佔有率，展現出持續強勁的市場成長動能。由於對先進傳染病檢查和更完善的醫療保健監測系統的需求不斷成長，該地區對分子診斷解決方案的需求仍然強勁。醫療保健和公共衛生機構越來越重視早期診斷、定期篩檢計畫和預防性醫療保健策略。分子診斷技術具有高準確性和高靈敏度，使醫療專業人員能夠及早發現疾病並加速治療決策。診斷基礎設施的持續進步和精準醫療方法的日益普及預計將進一步推動該地區的市場發展。

目錄

第1章：調查方法

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 全球技術進步和人們對早期疾病診斷重要性的認知不斷提高
    • 對即時診斷（POC）的需求日益成長
    • 老年人口增加
    • 增加研發投入
  • 產業潛在風險與挑戰
    • 分子診斷測試高成本
    • 熟練人員短缺
  • 市場機遇
    • 藥物基因體學以及伴隨診斷和精準醫療的整合
• 成長潛力分析
• 監理情勢
• 技術展望
  • 最新科技趨勢
  • 新興技術
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 專利分析
• 價格趨勢分析
• 波特的分析
• PESTLE分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估算與預測：依產品類型分類，2022-2035年

• 裝置
• 試劑和試劑盒

第6章 市場估計與預測：依技術分類，2022-2035年

• 聚合酵素鏈鎖反應（PCR）
• 雜交
• 定序
• 恒溫核酸增幅技術（INAAT）
• 微陣列
• 其他技術

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 感染疾病診斷
  • COVID-19
  • 流感
  • 呼吸道融合細胞病毒（RSV）
  • 結核
  • CT/NG
  • HIV
  • C型肝炎
  • B型肝炎
  • 其他感染疾病診斷
• 基因疾病檢測
• 腫瘤科檢查
• 其他用途

第8章 市場估算與預測：依測試環境分類，2022-2035年

• 實驗室測試
• 即時偵測 (POC)

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 醫院和診所
• 診斷檢查室
• 其他最終用戶

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第11章：公司簡介

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company（BD）
• Biocartis
• bioMerieux
• Bio-Rad Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Huwel Lifesciences
• Illumina, Inc.
• QIAGEN NV
• QuidelOrtho Corporation
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

The Global Molecular Diagnostics Equipment and Reagent Market was valued at USD 18.5 billion in 2025 and is estimated to grow at a CAGR of 7.6% to reach USD 38.6 billion by 2035.

The market growth is supported by continuous technological advancements, rising awareness about early disease detection, increasing demand for point-of-care (POC) diagnostic solutions, and the expanding global elderly population. Molecular diagnostics equipment and reagents include diagnostic instruments, analyzers, assay solutions, and consumables that identify and monitor diseases through the analysis of genetic materials such as DNA, RNA, and other molecular markers. These products are widely used in clinical diagnostics, infectious disease testing, cancer detection, genetic analysis, and research applications, while excluding software and informatics platforms. The increasing occurrence of infectious diseases, emergence of new pathogens, and recurring disease outbreaks are creating a strong need for faster and more precise diagnostic technologies. Healthcare systems are increasingly emphasizing early detection, accurate disease identification, and effective outbreak response, which is driving adoption of molecular diagnostic instruments, testing kits, and reagents across hospitals, laboratories, and research facilities.

The reagents and kits segment held 71.9% share in 2025. Reagents and kits represent essential components of molecular diagnostic workflows because they are required for conducting testing procedures across infectious disease screening, oncology applications, genetic diagnostics, and prenatal testing. Increasing laboratory testing volumes and the growing number of diagnostic procedures are creating consistent demand for these consumable products. In addition, advancements in assay development, enhanced multiplex testing capabilities, and specialized disease detection panels are improving the efficiency and accuracy of molecular diagnostics. The rising preference among laboratories and healthcare providers for reliable, standardized, and user-friendly testing solutions is further contributing to segment expansion.

The hospitals and clinics segment accounted for 45.9% share in 2025. Healthcare facilities are increasingly incorporating molecular diagnostic technologies into routine clinical practices for disease identification, treatment decisions, patient monitoring, and ongoing care management. Hospitals and clinics are benefiting from the wider integration of molecular testing into healthcare processes, particularly as demand increases for accurate diagnostic information. Growing patient volumes, increasing healthcare investments, and the need for improved diagnostic precision are encouraging medical facilities to enhance their molecular testing capabilities.

North America Molecular Diagnostics Equipment and Reagent Market 42.4% share in 2025 and continues to demonstrate strong market growth. The region maintains significant demand for molecular diagnostic solutions due to the increasing need for advanced infectious disease testing and improved healthcare surveillance systems. Healthcare organizations and public health institutions are placing greater focus on early diagnosis, routine screening programs, and preventive healthcare strategies. Molecular diagnostic technologies provide high accuracy and sensitivity, allowing healthcare providers to identify diseases at earlier stages and support faster treatment decisions. Continued advancements in diagnostic infrastructure and increasing adoption of precision healthcare approaches are expected to strengthen regional market development.

Key players operating in the global molecular diagnostics equipment and reagent industry include Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., bioMerieux, Roche, Illumina, Inc., Agilent Technologies, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Siemens Healthineers AG, QIAGEN N.V., Hologic, Inc., Biocartis, QuidelOrtho Corporation, Huwel Lifesciences, and Sysmex Corporation. Companies operating in the molecular diagnostics equipment and reagent market are implementing strategies such as product innovation, strategic partnerships, research and development investments, and expansion of diagnostic portfolios to improve their competitive position. Market participants are focusing on developing faster, more accurate, and easy-to-use molecular testing solutions to address evolving healthcare requirements. Companies are also investing in advanced assay technologies, automation capabilities, and expanded testing applications to increase adoption across hospitals, laboratories, and research facilities. Collaborations with healthcare organizations and research institutions are helping manufacturers improve product performance and market reach.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy and data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail and confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Product type trends
  • 2.2.2 Technology trends
  • 2.2.3 Application trends
  • 2.2.4 Test setting trends
  • 2.2.5 End use trends
  • 2.2.6 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Technological advances and increasing awareness towards early disease diagnosis globally
    • 3.2.1.2 Escalating demand for POC diagnostics
    • 3.2.1.3 Increasing geriatric population base
    • 3.2.1.4 Increasing number of R&D initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of molecular diagnostic tests
    • 3.2.2.2 Lack of skilled personnel
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration of pharmacogenomics and companion diagnostics with precision medicine
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by primary research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by primary research)
• 3.7 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.8 Patent analysis
• 3.9 Pricing trend analysis (Driven by primary research)
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagents and kits

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Polymerase chain reaction (PCR)
• 6.3 Hybridization
• 6.4 Sequencing
• 6.5 Isothermal nucleic acid amplification technology (INAAT)
• 6.6 Microarrays
• 6.7 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious disease diagnostics
  • 7.2.1 COVID-19
  • 7.2.2 Flu
  • 7.2.3 Respiratory syncytial virus (RSV)
  • 7.2.4 Tuberculosis
  • 7.2.5 CT/NG
  • 7.2.6 HIV
  • 7.2.7 Hepatitis C
  • 7.2.8 Hepatitis B
  • 7.2.9 Other infectious disease diagnostics
• 7.3 Genetic disease testing
• 7.4 Oncology testing
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Test Setting, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Laboratory-based Tests
• 8.3 Point-of-Care (POC) Tests

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Diagnostic Laboratories
• 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Agilent Technologies
• 11.3 Becton, Dickinson and Company (BD)
• 11.4 Biocartis
• 11.5 bioMerieux
• 11.6 Bio-Rad Laboratories
• 11.7 Danaher Corporation
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Hologic, Inc.
• 11.10 Huwel Lifesciences
• 11.11 Illumina, Inc.
• 11.12 QIAGEN N.V.
• 11.13 QuidelOrtho Corporation
• 11.14 Siemens Healthineers AG
• 11.15 Sysmex Corporation
• 11.16 Thermo Fisher Scientific Inc.